2020年非布索坦最新价格

The latest price of febuxostat in 2020. The latest price of febuxostat (febuxostat, feburic) in China is around 1,000$ per box. The generic version of Febuxostat produced by Zydus Pharmaceuticals in India has the same efficacy as the original drug, but is much cheaper. The price is about 80$ for 80mg*30 tablets/box, and about 200$ for 40mg*100 tablets/box. Due to exchange rate fluctuations, the price cannot be accurate. Medical Companion Travel is an overseas medical service company. For specific price information of Febuxostat, patients can consult the Medical Companion Travel Service of a regular overseas medical service company.

Febuxostat (febuxostat, feburic) is a new type of selective new non-purine xanthine oxidase (XO) inhibitor. The main component is febuxostat. The drug was approved by the U.S. Food and Drug Administration (FDA) for marketing in the United States in February 2009. In 2010, it was launched in France, the United Kingdom, Germany and other countries. Fibuxostat was officially launched in China on June 26, 2013.

Febuxostat (febuxostat, feburic) and allopurine are both drugs for the treatment of gout, but febuxostat has obvious advantages:

(1) Allopurinol only inhibits the reduced form of XOR, while febuxostat (febuxostat, feburic) has a significant inhibitory effect on both oxidized and reduced forms of XOR, so its uric acid-lowering effect is more powerful and lasting;

(2) Since allopurinol is a purine analogue, it will inevitably affect the activities of other enzymes involved in purine and pyridine metabolism. Therefore, repeated high-dose administration is required to maintain high drug levels during allopurinol treatment. This also leads to serious or even fatal adverse reactions due to drug accumulation. Febuxostat (febuxostat, feburic) is a non-purine XOR inhibitor and therefore has a better safety profile.